TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Celltrion USA and Express Scripts Collaborate to Extend Access to ZYMFENTRA™, the Initial FDA-Approved Subcutaneous Infliximab for Autoimmune Disorders

Monday, April 29, 2024

Celltrion USA has recently entered into an important agreement with Express Scripts, a leading pharmacy benefit manager (PBM) representing more than 100 million individuals covered by health plans. Effective April 4, 2024, this agreement allows for the inclusion of ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary, serving approximately 21.9 million insured lives. ZYMFENTRA™ (infliximab-dyyb) will now be accessible for inclusion in the formularies of plan participants, such as Health Plans of the PBM.

Celltrion USA, highlighted the significance of this agreement in expanding treatment access for millions of patients dealing with chronic diseases. She reiterated the company's commitment to collaborating with providers, patients, and physicians to advance therapies addressing chronic debilitating conditions.

As the first and only FDA-approved subcutaneous infliximab available in the U.S., ZYMFENTRA represents a milestone in therapeutic options for autoimmune diseases. Celltrion USA is actively engaging with both national and regional health plans, as well as Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs), to underscore the value of its FDA-approved therapies and secure comprehensive coverage, including ZYMFENTRA.

ZYMFENTRA™ (infliximab-dyyb) is prescribed for adults as a subcutaneous injection for the maintenance treatment of moderately to severely active ulcerative colitis and Crohn's disease. By blocking the action of tumor necrosis factor-alpha (TNF-alpha), ZYMFENTRA helps mitigate the immune system's attack on healthy tissues, offering relief to patients.

Approved by the FDA through the Biologics License Application (BLA) under the 351(a) pathway of the Public Health Service Act, ZYMFENTRA represents a new biologic with a first-approved subcutaneous administration form. It is protected under patent law for its dosage form until 2037 and for its route of administration until 2040.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit